HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified)
表達區(qū)間及表達系統(tǒng)（Source）
HRSV (A) Fusion glycoprotein F0, His Tag (RSF-V52H6) is expressed from human 293 cells (HEK293).
Predicted N-terminus: Gln 26
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 55.2 kDa. The protein migrates as 47-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
After reconstitution, this product is stable after storage at -70°C for 3 months.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
For long term storage, the product is stable for up to 3 years at -70°C from date of receipt;
For short term storage, the product is stable for up to 12 months at 2-8°C from date of receipt.
背景（Background）
人呼吸道合胞病毒（HRSV）是嬰兒急性下呼吸道疾病最常見的病原體，可導(dǎo)致終身反復(fù)感染。RSV融合糖蛋白（RSV F）是人血清中RSV中和抗體的主要靶標(biāo)。RSV F是一種I型病毒融合蛋白，合成為無活性的單鏈多肽，組裝成三聚體。RSV F通過不可逆的蛋白質(zhì)折疊將病毒和宿主細胞膜從不穩(wěn)定的融合前構(gòu)象融合到穩(wěn)定的融合后構(gòu)象。這兩個州都表現(xiàn)出被中和抗體靶向的表位，融合后的RSV F正在被開發(fā)為候選疫苗。
關(guān)鍵字： HRSV;HRSV蛋白;人類呼吸道合胞病毒A;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。